Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD2275 + AZD2284 + AZD2287 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD2275 | AZD-2275|AZD 2275 | Limited information is currently available on AZD2275 (Mar 2025). | ||
| AZD2284 | AZD-2284|AZD 2284 | AZD2284 is a radioconjugate comprising a monoclonal antibody targeting STEAP2 linked to a DOTA chelate and the radionuclide actinium-225, which potentially inhibits tumor growth (Cancer Res (2025) 85 (8_Supplement_1): 4303). | ||
| AZD2287 | AZD-2287|AZD 2287 | Limited information is currently available on AZD2287 (Mar 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06879041 | Phase I | AZD2275 + AZD2284 + AZD2287 AZD2275 + AZD2287 AZD2284 + AZD2287 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | AUS | 1 |